| 
			  
			  
			
  by Matthew Perrone
 
			AP Health WriterNovember 9, 2010
 
			from
			
			LATimes Website 
			  
			  
			WASHINGTON (AP)
 
			  
			For the second time this year, federal 
			inspectors have dismissed allegations by
			
			Food and Drug Administration 
			(FDA) 
			scientists who say they were pressured and harassed by their 
			managers into approving medical devices against their judgment.
 The office of inspector general for the Department of Health and 
			Human Services, which oversees the FDA, concluded there is "no 
			evidence of retaliation" against the employees, according to a 
			one-page memo obtained by The Associated Press.
 
			  
			The memo, dated Oct. 
			14, concludes "this case is closed."
 The inspector general reached a similar finding in February, but 
			agreed to reopen the investigation at the request of federal 
			lawmakers and advocacy groups, including the Project on Government 
			Oversight. The groups complained that the previous investigation was 
			too narrow and did not look into allegations of misconduct that fell 
			short of criminal violations.
 
 A spokesman for the inspector general declined to comment beyond the 
			memorandum.
 
 Nine current and former FDA medical device reviewers have alleged 
			since 2008 that agency managers improperly overruled their opinions 
			and tried to intimidate them when they went public with their 
			concerns. At issue are 
			
			CT scanners and other medical 
			devices that use radiation to detect or treat diseases.
 
			  
			Many of the devices allow lifelike 
			pictures of the human anatomy, but carry a higher risk from 
			radiation than older scans such as X-rays.
 In the last year, hundreds of radiation overdoses have been reported 
			with imaging devices, particularly CT scanners, used by hospitals 
			across the country. The whistleblowers have argued that these 
			problems underscore the concerns they raised about such devices.
 
 But in a separate announcement Tuesday, the FDA said it has 
			concluded that CT scanners are safe when used properly. After more 
			than a year of investigation, the agency said, the overdoses 
			probably resulted from improper use by imaging technicians.
 
 The agency recommends several manufacturing changes to make scanners 
			safer to use, including automatic warnings that alert machine 
			operators when radiation doses exceed recommended levels.
 
 The FDA whistleblowers point to multiple occasions in which managers 
			overruled their rejections of medical scanners, without properly 
			documenting the reason, as required by FDA regulations. At least 
			three of the whistleblowers have left the agency in the last year, 
			saying their contracts were terminated after they sent letters of 
			complaint to Congress, the administration and other outside groups.
 
 One of those whistleblowers, Dr. Julian Nicholas, said he has 
			never been interviewed by the inspector general's office.
 
			  
			Nicholas, an Oxford-trained intestinal 
			specialist, said that his contract as a medical reviewer was 
			terminated after he repeatedly opposed approving a CT scanner for 
			routine colon cancer screening. Nicholas said that he objected to 
			exposing otherwise healthy patients to the cancer risks of routine 
			radiation scans. 
				
				"It's hard for me to believe this 
				was a bona fide investigation when they haven't even contacted 
				the people who reported these violations," said Nicholas, now a 
				practicing gastroenterologist at the Scripps Clinic in San 
				Diego.    
				"Such a huge amount of money is at 
				stake and so many people are affected, that for the (office of 
				inspector general) not to conduct a credible investigation is 
				criminal in itself." 
			FDA's device leadership shared the 
			results of the latest investigation with employees last week, 
			according to a Nov. 5 e-mail obtained by The Associated Press.
 The e-mail was written by Dr. Jeffrey Shuren, head of the 
			FDA's Center for Devices and Radiological Health, to members 
			of his staff.
 
			  
			In it he said the investigation found no 
			evidence of retaliation against the scientists who complained nor 
			of, 
				
				"material violation of rules with 
				respect to documenting significant decisions." 
			Shuren pointed out in his e-mail that 
			the FDA hired a private contractor last spring to review the device 
			unit's structure and make recommendations for improving relations 
			between scientists and management.  
			  
			The contractor recommended changes in 
			internal communications and training opportunities, Shuren said. 
			  
			    |